Home › Companies › PALI

Pipeline (3 active programs)

Capital (as filed)

Cash

$125M cash and cash equivalents · Jun 30, 2026 (10-Q)

Operating cash flow

−$7.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$133M cash, runway 2H27 readout per the update of Sep 22, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

• 2026-09-23 UPDATE: Palisade Bio (PALI) - The Second Shot Gets Cleared 🔒 Paid
• 2026-08-06 Palisade Bio (PALI) - Scientific Deep Dive for PALI-2108 and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Palisade Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-08-06 Watch Palisade Bio (PALI) - Scientific Deep Dive for PALI-2108 and Pipeline Products The prodrug engineering is real and the balance sheet funds the binary, but PDE4 failed its one controlled UC trial, Phase 2 doses are below the regimen that generated the clinical signal, and there is no issued U.S. patent under a ~$457M market cap.
2. 2026-09-23 Watch UPDATE: Palisade Bio (PALI) - The Second Shot Gets Cleared FDA IND clearance for ASCENTRA-CD is a clean execution milestone but does not advance or de-risk the ASCENTRA-UC Week 12 readout that constitutes the entire valuation; the dose discontinuity and absent U.S. patent remain unresolved.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-08-10 8-K in filings ↓

  • “Phase 2 CD clinical trial commencement targeted for 1Q 2027”

    matched to PALI-2108 (CD) · topline data · read as 1Q 2027 / matched to PALI-2108 (CD) · regulatory submission · read as 1Q 2027
• 2026-08-10 8-K in filings ↓

  • “Phase 2 CD clinical trial commencement targeted for 1Q 2027”

    matched to PALI-2108 (CD) · regulatory submission · read as 1Q 2027

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (24)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Oct 28, 2026ReleasePalisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative ColitisASCENTRA-UC has dosed its first patient — the trial I called "the entire valuation" is now enrolling — while ACG data partially addresses the β-glucuronidase variability risk and the dose discontinuity that were the two biggest structural questions I left open.
• Oct 20, 2026ReleasePalisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026via aggregatorBD extracted 1 program update from this document → PALI pipeline
• Oct 12, 2026ReleasePalisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026via aggregatorBD extracted 1 program update from this document → PALI pipeline
• Sep 28, 2026ReleasePalisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026via aggregator
• Sep 23, 2026ReleasePalisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearancevia aggregator
• Sep 22, 2026ReleasePalisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBDvia aggregator→ BD updatePalisade Bio just cleared the FDA IND for ASCENTRA-CD — the Crohn's disease Phase 2 I flagged in the deep dive — locking in a Q1 2027 first patient and Q1 2028 readout, with a trial design that answers some questions and raises others about the single-arm, open-label structure the original writeup warned about.
• Sep 21, 2026ReleasePalisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
• Sep 4, 2026ReleaseGut-Targeted Inhibition of Phosphodiesterase 4 with PALI-2108 Demonstrates Early Endoscopic and Biomarker Improvements in Fibrostenotic Crohn’s Disease: Results From a Phase 1b StudyBD extracted 1 program update from this document → PALI pipeline
• Sep 4, 2026ReleaseThe Microbiome-Activated Phosphodiesterase (PDE)-4 Inhibitor, PALI-2108 Leads to Rapid Clinical and Histologic Improvement in Moderate-to-Severe Ulcerative Colitis: A Phase1a/1b Study
• Sep 4, 2026ReleasePALI-2108, a Next-Generation Oral PDE4 Inhibitor Prodrug, Demonstrates Localized Ileocolonic Exposure with Favorable Tolerability in IBD
• Sep 4, 2026ReleaseDevelopment of Mucosal Transcriptomic Signatures to Predict Response to the Microbiome-Activated Phosphodiesterase (PDE)-4 Inhibitor PALI-2108 in Ulcerative Colitis
• Sep 4, 2026ReleaseMicrobiome Beta-Glucuronidase Activity Does Not Limit Bioconversion or Pharmacokinetic Consistency of the Colon-Targeted PDE4 Prodrug PALI-2108 in Ulcerative Colitis
• Sep 3, 2026ReleasePalisade Bio to Participate in Upcoming Investor Conferences
• Aug 10, 2026ReleasePalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentBD extracted 1 program update from this document → PALI pipeline
• Aug 10, 20268-KCurrent report: results of operations · EX-99.1
• Aug 10, 202610-QQuarterly report
• Jun 11, 20268-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
• May 12, 2026S-3Shelf registration
• May 12, 20268-KCurrent report: results of operations · EX-99.1
• May 12, 202610-QQuarterly report
• Apr 29, 2026DEFA14AProxy soliciting material
• Apr 29, 2026DEF 14AProxy statement
• Apr 2, 20268-KCurrent report: other events
• Mar 20, 202610-KAnnual report